Exploring the optimal reference to estimate the effect of anti-inflammatory therapy for the cardiac sarcoidosis -metabolic volume assessment of FDG PET-

1542Objectives: Cardiac sarcoidosis (CS) is rare but a potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and most notably sudden cardiac death. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays important roles not only in the diagnosis of CS but also in the evaluation of therapeutic effects of anti-inflammatory therapy. A volume-based analysis by FDG PET including cardiac metabolic volume (CMV) has emerged as a new assessment tool for measuring the volume within the boundary determined by reference tissue such as the liver and the blood pool uptake. However, oral steroid therapy could affect the uptake in the liver or in the blood pool uptake. Here, we attempted to evaluate and analyze the steroid effects on the liver and the blood pool uptake. Methods: A total of consecutive 38 patients who underwent FDG PET/CT for suspected or diagnosed CS were retrospectively enrolled. We assessed and compared the variation of liver and blood pool FDG uptake from pre- to during- steroid therapy. After the diagnosis of CS was established, oral steroid therapy was initiated. Daily maintenance dose of steroid was 27.6 ± 4.0 mg at the second scan and the duration between the scans was 61.5 ± 23.5 days. For the liver uptake, the threshold as SUVmean + 3 x standard deviation (SD) of the right lobe (RL) obtained from the semi-automated dedicated software and SUV assessed by manual process from th...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Cardiovascular Clinical Science Poster Session Source Type: research

Related Links:

Authors: Takuma K, Eri H, Satoshi I, Takashi O PMID: 30333400 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Cardiac resynchronization therapy (CRT) has been shown to be beneficial in patients with medically refractory heart failure. While it has been found to be effective in a wide range of etiologies for non-ischemic cardiomyopathy, its role in improving remodeling and survival of patients with cardiac sarcoidosis (CS) remains undefined. We performed a retrospective review of all patients at our institution with CS who underwent implantation of a CRT device between 2007 and 2017. The outcomes of this population were compared to the outcomes of a cohort of patients with non-ischemic cardiomyopathy with an etiology other than sarcoidosis.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 18 October 2018Source: Respiratory Medicine Case ReportsAuthor(s): Mari Tone, Nobuyasu Awano, Minoru Inomata, Naoyuki Kuse, Tatsunori Jo, Hanako Yoshimura, Yoshiaki Furuhata, Tamiko Takemura, Toshio Kumasaka, Takehiro IzumoAbstractCorrect staging of lung cancer is important for the selection of the best therapy, but discriminating between lymphadenopathy from lung cancer and from sarcoidosis by imaging examinations is difficult. Additionally, distinguishing lymphadenopathy of sarcoidosis from sarcoid reactions which are sometimes caused by lung cancer is difficult on imaging and pathologi...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
It was with great interest we read the article by Dr. Collins and colleagues published in the August 2018 edition of Respiratory Medicine, titled “Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?” The authors describe the characteristics of a disease entity they coined “combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF)” [1]. We appreciate the authors’ efforts to shed light on this cl inical entity, which to date has sparked debate in terms of proper classification of patients who share radiographic and histopathologic features of sarcoidosis an...
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Tags: Correspondence Source Type: research
Immunotherapy,Volume 10, Issue 14, Page 1189-1192, October 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Extrathoracic Sarcoidosis Interventions:   Drug: Infliximab;   Drug: Placebo Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Extrathoracic Sarcoidosis Interventions:   Drug: Infliximab;   Drug: Placebo Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiovascular | CT Scan | Heart | Laboratory Medicine | Liver | Nuclear Medicine | PET Scan | Sarcoidosis | Science | Statistics | Steroid Therapy | Sugar | Urology & Nephrology